CClinicalTrials.gg
CompletedNCT04720963Updated Sep 8, 2023

Intranasal Remimazolam for Premedication in Pediatric Patient

A Phase 4 interventional study of Remimazolam and Distilled water for injection in Sedative; Anxiety Disorder, sponsored by Second Affiliated Hospital of Wenzhou Medical University. Completed at 1 site in China. Open to participants aged 2 Years to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Second Affiliated Hospital of Wenzhou Medical University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
2 Years to 5 Years
Sex
All
01

Study summary

Anesthetic inhalation induction could be one of the most stressful experiences for children during the perioperative period, with almost 50% of them showing anxiety. It is an essential challenge for pediatric anesthesiologists on how to decrease anxiety for children in the operating room (OR) environment and to facilitate a smooth induction of anesthesia. Various factors like parental separation, unfamiliar surroundings, fear of physicians and needle injections can increase their preoperative anxiety. The researchers conducted the current study to investigate whether intranasal remimazolam can reduce anxiety in children before surgery.

Read the detailed description

children aged 2-5 years old were randomly allocated into three equal groups based on the premedication routes: Group R with intranasal remimazolam, Group D with intranasal dexmedetomidine and Group P with intranasal placebo, respectively.

02

Conditions studied

  • Sedative; Anxiety Disorder

Browse trials for

Keywords

  • remimazolam
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 90 is above the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Second Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 133 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. with American Society of Anesthesiologists (ASA) physical status I or II;
  2. aged 2-5 years;
  3. children with weight for age within the normal range
  4. were scheduled surgery with general anesthesia

Exclusion criteria

Exclusion Criteria:

  1. Children who had gastrointestinal,Cardiovascular or endocrine dysfunction;
  2. contraindication to preoperative sedation or had a known allergy or hypersensitive reaction to either dexmedetomidine or remimazolam;
  3. with any nasal pathology,organ dysfunction;
  4. recently respiratory infection, mental disorder;
  5. other reasons that researchers hold it is not appropriate to participate in this trial.-
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Placebo comparator
    group P (Placebo group)

    intranasal placebo about 30min before anesthesia induction

    Other: Distilled water for injection

  • Experimental
    group R (remimazolam group)

    intranasal remimazolam about 30min before anesthesia induction

    Drug: Remimazolam

  • Active comparator
    group D (Dexmedetomine group)

    intranasal dexmedetomidine about 30min before anesthesia induction

    Drug: Dexmedetomidine

Interventions

  • DrugRemimazolam

    intranasal remimazolam

  • OtherDistilled water for injection

    intranasal distilled water for injection

  • DrugDexmedetomidine

    Intranasal dexmedetomidine

06

What researchers measure

Primary outcomes

  1. The level of anxiety

    The Modified Yale Preoperative Anxiety Scale: The 22-item measure has five behavioural categories: activity, emotional expressivity, alertness and arousal, vocalizations, and interaction with parents. Total scores range from 23.33 through 100 with higher scores indicating greater anxiety.

    Time frame: up to 30 minutes after study drug given

Secondary outcomes

  1. The level of sedation

    Ramsay score 1. Patient anxious or agitated or both 2. Patient cooperative, oriented and tranquil 3. Patient responds to commands only 4. A brisk response to a light glabellar tap 5. A sluggish response to a light glabellar tap 6. No response higher scores mean a higher levels of sedation.

    Time frame: up to 30 minutes after study drug given

  2. the compliance of study drug given

    behavior score 1. Clam and cooperative; 2. Anxious but reassurable; 3. Anxious but not reassurable; 4. Crying, or resisting The scores of 1 and 2 signified satisfactory compliance, whereas scores of 3 and 4 were classified as poor compliance.

    Time frame: up to 30 minutes before anesthesia induction

  3. Parental separation anxiety scale

    A four-point parental separation anxiety scale as follows: 1. Easy separation, 2. Whimpers, but is easily reassured, not clinging, 3. Cries and cannot be easily reassured, but not clinging to parents, 4. Crying and clinging to parents. The scores of 1 and 2 signified acceptable separation whereas scores of 3 and 4 were classified as difficult separation.

    Time frame: up to 30 minutes after study drug given

  4. The degree of cooperation during inhalation anesthesia induction

    Induction Compliance Checklist range from 0 through 10,and lower scores indicate the higher degree of cooperation during inhalation anesthesia induction

    Time frame: intraoperative, (During inhalation anesthesia induction)

  5. Mask acceptance scale,MAS

    Mask acceptance scale,MAS 1. terrified, crying, agitated 2. moderate fear, not calmed with reassurance 3. slight fear of mask, easily calmed 4. unafraid, cooperative, accepts mask readily The scores of 3 and 4 signified satisfactory mask acceptable whereas scores of 1 and 2 were classified as poor mask acceptable.

    Time frame: intraoperative, (During inhalation anesthesia induction)

  6. Pediatric anesthesia emergence delirium scale,PAEDs

    The pediatric anesthesia emergence delirium scale consists of four items. Each item is scored 0-4 yielding a total between 0 and 20. The degree of emergence delirium increased directly with the total score.pediatric anesthesia emergence delirium scale ≥12 at any time indicates presence of emergence delirium.

    Time frame: Within up to 15-30 minutes after child's first eye opening in the postoperative period

  7. Recovery times

    The time from discontinuation of sevoflurane to the first open eye of the children and to achieve aldrete≥9

    Time frame: Within up to 30 minutes after child's first eye opening in the postoperative period

  8. Number of children with adverse effects

    Number of children with adverse effects 1. Bradycardia and/or hypotension need for hemodynamic support 2. Desaturation is defined as Oxygen desaturation \<90% 3. Any adverse effects requiring interventions

    Time frame: Up to 24 hours including preoperative, intraoperative, and postoperative periods

07

Study locations

1 site
  • The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04720963
Lead sponsor
Second Affiliated Hospital of Wenzhou Medical University
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Feb 7, 2021
Primary completion
Feb 28, 2022
Completion
Feb 28, 2022
Last update
Sep 8, 2023

Study contacts

Huacheng Liu
study chair · Second Affiliated Hospital of Wenzhou Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion